Abstract:17099 Background: Prolonged infusion of gemcitabine have shown increased levels of the active triphosphate metabolite that theorically could increase the response rate and toxicity. The objectives of this study were to evaluated the efficacy and safety of this combination of using gemcitabine as a rate infusion of 10 mg/m2 per min with carboplatin in front-line chemonaive patients with advanced NSCLC. Methods: Fifty-four chemonaive patients have been included. 44 were male and 10 female. Median age was 63 years (19–75). 13% had ECOG 0 and 53.7% ECOG 1 and 33.3% ECOG 2. 32 (59.2%) patients had adenocarcinoma, 13 (24.1%) squamous cell, 1 (1.9%) large cell carcinoma, and 8 (14.8%) others. Eight (14.8%) had stage IIIB and 46 (85.2%) stage IV. Treatment was consisted of 1200 mg/m2 gemcitabine given as a 2-hour continuous infusion (10 mg/m2 per min) on days 1 and 8 of each cycle an AUC 5 carboplatin as on day 1, repeating each cycle every 21 days. A total of 223 chemotherapy cycles were administered, with a median of 4 cycles per patient (range 1–6), and 15 (27.8%) patients received all six cycles. Results: Of the fifty-four patients enrolled, all were evaluated for toxicity (according to the WHO scale) and 51 assessed for response (according to the RECIST criteria), the overall response rate (ORR) was 41.2% (95% confidence interval, 28% to 57%), including two complete responses (CRs: 3.9%) and 19 partial responses (PRs: 37.3%). As per the intent-to-treat (ITT) analysis, the ORR was 38.9%. With a median follow-up time of 10.8 months, the median TTP was 5.0 months (range 3.7–6.3 months), median OS time was 11.5 months (range 9.9–13.1 months) and 1-year survival was 41.7% (95% CI 26% to 57%) and 2-year survival was 19.3% (4.4% to 34.2%).The main grade 3–4 toxicity consisted of neutropenia (55.6%) and thrombocytopenia (57.4%).Patients were required platelet transfusion in 27 cycles (12.1%) and haematopoietic growth factors support care in 56 (25.1%) cycles. No bleeding episodes were recorded. Grade 3 nausea/vomiting occurred in 5.6% and grade 1–2 skin rash occurred in 42.6%. Conclusions: Prolonged gemcitabine infusion combined with carboplatin is manageable tolerated and its efficacy is similar to that of other chemotherapeutic schemes used for NSCLC treatment. No significant financial relationships to disclose.

Comparison of Pharmacokinetics, Efficacy and Toxicity Profile of Gemcitabine Using Two Different Administration Regimens in Chinese Patients with Non-Small-cell Lung Cancer

Pharmacokinetics of Gemcitabine in Chinese Patients with Non-Small-cell Lung Cancer

Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small-cell Lung Cancer.

The Efficacy and Relationship Between Peak Concentration and Toxicity Profile of Fixed-Dose-Rate Gemcitabine Plus Carboplatin in Patients with Advanced Non-Small-Cell Lung Cancer

Phase II Trial of a 2-Hour Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

Clinical Observation on Gemcitabine 6h Prolonged Infusion Regimen in the Treatment of Advanced Non-Small-cell Lung Cancer

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Phase II Trial of Gemcitabine Plus Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer

Clinical Evaluation of delayed infusion of low dose gemcitabine combined with cisplatin maintenance chemotherapy regimens for treatment of advanced NSCLC patients

Efficacy of Third‐generation Chemotherapeutic Agents Combined with Cisplatin or Carboplatin in 3100 Chinese Patients with Advanced Non‐small‐cell Lung Cancer

Pharmacokinetics study of gemcitabine and its metabolite in Chinese patients with malignant tumor

Clinical trial of advanced non-small cell lung cancer by combination of gemci-tabine and cisplatin

Comparison of Gemcitabine/carboplat in Versus Paclitaxel/cisplatin for the Management of Non Small Cell Lung Cancer

Clinical Observation of Gemcitabine Administered in the Manner of Fixed Dose Rate in Advanced Malignant Tumor Patients of 31 Cases

Pulmonary Gemcitabine Delivery for Treating Lung Cancer: Pharmacokinetics and Acute Lung Injury Aspects in Animals.

Treatment of advanced non-small cell lung cancer with gemcitabine or docetaxel in combination with cisplatin:a systematic review

[Phase II Trial of Prolonged Infusion of Low-Dose Gemcitabine in Advanced Non-Small Cell Lung Cancer Treatment].

Efficacy of Gemcitabine and Vinorelbine in First-line Treatment with Advanced Non-small Cell Lung Cancer: A Multicentre Retrospective Study

Comparison of Fixed-dose Rate Gemcitabine Infusion Combined with Oxaliplatin and Routine GEMOX Regimen in Treatment of Patients with Advanced Hepatocellular Carcinoma